Comparison of clinical characteristics and assessment scale scores between patients with and without suspected COVID-19
| COVID-19 suspected group (n=21) | Clean group (n=30) | t/Z/χ2 | P value | |
| Age (years), mean (SD) | 43.1 (2.6) | 45.0 (9.2) | −0.626 | 0.543 |
| Female and male, n (%) | 9 (42.9) | 15 (50) | 0.253 | 0.615 |
| Comorbidities, n (%) | 8 (38.1) | 4 (13.3) | 2.946 | 0.086 |
| Psychiatric medications, n (%) | ||||
| Antidepressants | 1 (4.8) | 0 (0) | 0.412 | |
| Mood stabiliser | 7 (33.3) | 5 (16.7) | 1.907 | 0.167 |
| Benzodiazepines | 12 (57.1) | 5 (16.7) | 9.107 | 0.003* |
| Assessment scales, mean (SD) | ||||
| PANSS | 67.1 (19.5) | 61.5 (14.9) | 1.17 | 0.248 |
| PSS | 26.5 (6.0) | 11.6 (4.0) | 9.907 | <0.001* |
| HAMD | 14.1 (8.1) | 0.4 (0.8) | −6.318 | <0.001* |
| HAMA | 13.9 (9.3) | 2.2 (2.1) | −5.099 | <0.001* |
| PSQI | 8.0 (3.8) | 4.7 (3.6) | −2.835 | 0.005* |
*P<0.05.
HAMA, Hamilton Anxiety Rating Scale; HAMD, Hamilton Depression Rating Scale; PANSS, Positive and Negative Syndrome Scale; PSQI, Pittsburgh Sleep Quality Index; PSS, Perceived Stress Scale.